Healthcare -
Biotechnology - NASDAQ - US
$ 0.36
3.39 %
$ 14.1 M
Market Cap
-0.16
P/E
1. INTRINSIC VALUE
Balance Sheet
Athira Pharma, Inc.
| Current Assets | 54.8 M |
| Cash & Short-Term Investments | 51.3 M |
| Receivables | 0 |
| Other Current Assets | 3.57 M |
| Non-Current Assets | 3.94 M |
| Long-Term Investments | 0 |
| PP&E | 3.25 M |
| Other Non-Current Assets | 686 K |
| Current Liabilities | 13.1 M |
| Accounts Payable | 319 K |
| Short-Term Debt | 414 K |
| Other Current Liabilities | 12.4 M |
| Non-Current Liabilities | 803 K |
| Long-Term Debt | 803 K |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Athira Pharma, Inc.
| Revenue | 0 |
| Cost Of Revenue | 0 |
| Gross Profit | 0 |
| Operating Expenses | 101 M |
| Operating Income | -96.8 M |
| Other Expenses | 165 K |
| Net Income | -96.9 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Athira Pharma, Inc.
| Net Income | -96.9 M |
| Depreciation & Amortization | 455 K |
| Capital Expenditures | -33 K |
| Stock-Based Compensation | 11 M |
| Change in Working Capital | -12 M |
| Others | -7.86 M |
| Free Cash Flow | -97.2 M |
Wall Street Analysts Price Targets
Athira Pharma, Inc.
ATHA has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
ATHA does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Athira Pharma, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
31.4 K USD 5
6-9 MONTHS
0 USD 0
9-12 MONTHS
7.86 K USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
100 K USD 1
9-12 MONTHS
7. News
ATHA Completes Ground Geophysics and Commences 2025 Angilak Diamond Drill Exploration Program
HIGHLIGHTS The 2025 Angilak Exploration Program will comprise ~10,000 m of diamond drilling with two objectives: Lac 50 Deposit - expansion of the footprint of uranium mineralization. Stepping out along strike and at depth from the 2024 Exploration Target (as defined below), which remains open and unconstrained.
accessnewswire.com
- 2 weeks ago
Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit
Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical development
globenewswire.com
- 1 month ago
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25
globenewswire.com
- 1 month ago
Athena Gold Closes Oversubscribed Flow-Through Financing
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VACAVILLE, CALIFORNIA / ACCESS Newswire / April 28, 2025 / Athena Gold Corporation (CSE:ATHA)(OTCQB:AHNRF) ("Athena Gold" or the "Company") is pleased to announce the closing of a non-brokered private placement of flow-through common shares (the "FT Shares") previously announced on April 7, 2025, as amended April 21, 2025 (the "FT Offering"). The Company issued an aggregate of 15,300,000 FT Shares at a price of CDN $0.05 per FT Share for gross proceeds of CDN$765,000, which represents an oversubscription of CDN$265,000 of the originally planned financing.
accessnewswire.com
- 1 month ago
ATHA Energy Announces Closing of Financing for Aggregate Gross Proceeds of $10,000,000
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 22, 2025 / ATHA Energy Corp. (TSXV:SASK)(FRA:X5U)(OTCQB:SASKF) ("ATHA" or the "Company") is pleased to announce that, further to its press releases dated March 31, 2025 and April 7, 2025, it has completed a fully-subscribed private placement offering of: (i) 16,766,490 flow-though common shares of the Company ("FT Shares") at a price of $0.47 per FT Share; and (ii) 3,475,000 FT Shares that may be immediately resold or donated to registered charities ("Charity FT Shares", and collectively with the FT Shares, the "Offered Shares") at a price of $0.61 per Charity FT Share for aggregate gross proceeds of approximately $10,000,000(the "Offering").
accessnewswire.com
- 1 month ago
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates
Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS)
globenewswire.com
- 3 months ago
ATHA Energy expands uranium potential at Angilak
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) revealed that a survey at its Angilak uranium project in Nunavut has expanded the known depth of uranium mineralization at the Lac 50 Deposit to over one kilometer. The survey also identified a new 25-kilometer conductive trend along the western margin of the Angikuni Basin, according to a statement from ATHA.
proactiveinvestors.com
- 5 months ago
Seattle biotech firm Athira Pharma will pay $4M to settle allegations related to research misconduct
Seattle-area biotech company Athira Pharma agreed to pay $4.
geekwire.com
- 5 months ago
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association's 35th International Symposium on ALS/MND
BOTHELL, Wash., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today presented preclinical data highlighting target engagement and neuroprotective effects of ATH-1105 in human motor neurons at the Motor Neurone Disease Association's 35th International Symposium on ALS/MND, taking place Dec. 6-8, 2024, in Montreal, Canada.
globenewswire.com
- 6 months ago
ATHA Energy identifies high-grade uranium mineralization in new outcrops at Angilak
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) said it has uncovered numerous outcrops hosting high-grade uranium mineralization at Angilak in Nunavut. The surficial mapping program, centered around the Lac 50 Deposit, identified mineralized outcrops between the Lac 48, Lac 50, Lac 52, and Lac 54 trends, according to a statement from ATHA.
proactiveinvestors.com
- 6 months ago
ATHA Energy reveals updated technical report for Angilak uranium project
ATHA Energy Corp (TSX-V:SASK, OTCQB:SASKF) has unveiled its updated 2024 technical report for its 100%-owned Angilak uranium project in Nunavut. The third-party updated technical report establishes a baseline Exploration Target for the Lac 50 Deposit of 60.8–98.2 million pounds of U₃O₈ (uranium) with an average grade range of 0.37–0.48% U₃O₈.
proactiveinvestors.com
- 6 months ago
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates
Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025 Expects to complete healthy volunteer Phase 1 clinical study of ATH-1105 by year end and begin dosing ALS patients in 2025
globenewswire.com
- 7 months ago
8. Profile
Summary
Athira Pharma, Inc. ATHA
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 14.1 M
Dividend Yield
0.00%
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.
Contact
18706 North Creek Parkway, Bothell, WA, 98011
https://www.athira.com
IPO
Date
Sept. 18, 2020
Employees
26
Officers
Dr. Javier San Martin M.D.
Chief Medical Officer
Mr. Mark F. Worthington J.D.
General Counsel, Chief Compliance Officer & Corporate Secretary
Ms. Julie Rathbun
Head of Investor Relations
Dr. Kevin Church Ph.D.
Chief Scientific Officer
Mr. Robert Renninger
Senior Vice President of Finance & Accounting, Principal Financial Officer and Principal Accounting Officer
Dr. Mark J. Litton M.B.A., Ph.D.
President, Chief Executive Officer & Director